BIOMERICA INC
Business
Biomerica Inc. is a global biomedical technology company that develops, manufactures, and markets diagnostic test kits analyzing blood, urine, nasal, or fecal samples to diagnose diseases, food intolerances, and medical conditions. Products include rapid point-of-care tests and laboratory-based diagnostics, with flagship offerings like inFoods® IBS (for identifying foods triggering IBS symptoms) and hp+detect™ (for Helicobacter pylori detection). The company sells primarily through clinical laboratories and point-of-care settings to domestic and international markets via direct sales, distributors, and e-commerce channels.
Summary from 10-K filed 2025-08-29
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-05-31 | FY 2024 2024-05-31 | FY 2023 2023-05-31 | FY 2022 2022-05-31 | FY 2021 2021-05-31 |
|---|---|---|---|---|---|---|
| Net sales | 5 | 5 | 5 | 19 | 7 | |
| Cost of sales | −5 | −5 | −5 | −16 | −7 | |
| Gross profit | 498,000 | 611,000 | 446,000 | 3 | 366,285 | |
| Selling, general and administrative | 5 | 5 | 6 | 6 | 6 | |
| Research and development | 1 | 1 | 2 | 2 | 2 | |
| Total operating expense | 6 | 7 | 8 | 8 | 8 | |
| Loss from operations | −5 | −6 | −7 | −5 | −7 | |
| Dividend and interest income | 165,000 | 431,000 | 133,000 | — | — | |
| Total other income | 165,000 | 431,000 | 134,000 | 27,000 | 66,496 | |
| Loss before income taxes | −5 | −6 | −7 | −5 | −7 | |
| Provision for income taxes | −1,000 | −42,000 | −51,000 | −24,000 | −13,000 | |
| Net loss | −5 | −6 | −7 | −5 | −7 | |
| Basic net loss per common share | −2.16 | −2.84 | −0.5 | −0.36 | −0.62 | |
| Diluted net loss per common share | −2.16 | −2.84 | −0.5 | −0.36 | −0.62 | |
| Basic | 2 | 2 | 14 | 13 | 12 | |
| Diluted | 2 | 2 | 14 | 13 | 12 | |
| Foreign currency translation | −3,000 | 8,000 | −36,000 | −26,000 | −8,115 | |
| Comprehensive loss | −5 | −6 | −7 | −5 | −7 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-05-31 | FY 2024 2024-05-31 | FY 2023 2023-05-31 | FY 2022 2022-05-31 | FY 2021 2021-05-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 2 | 4 | 10 | 6 | 4 | |
| Accounts receivable, net | 731,000 | 947,000 | 722,000 | 774,000 | 1 | |
| Inventories, net | 1 | 2 | 2 | 2 | 3 | |
| Prepaid expenses and other | 255,000 | 238,000 | 300,000 | 320,000 | 370,290 | |
| Total current assets | 5 | 8 | 13 | 9 | 9 | |
| Property and equipment, net of accumulated depreciation and amortization | 135,000 | 201,000 | 213,000 | 214,000 | 311,000 | |
| Right-of-use assets, net of accumulated amortization of $1,223,000 and $910,000 as of May 31, 2025 and 2024, respectively | 429,000 | 742,000 | 1 | 1 | 2 | |
| Investments | 165,000 | 165,000 | 165,000 | 165,000 | 165,324 | |
| Intangible assets, net of accumulated amortization of $69,000 and $48,000 as of May 31, 2025 and 2024, respectively | 228,000 | 212,000 | 165,000 | 170,000 | 295,000 | |
| Other assets | 113,000 | 203,000 | 79,000 | 96,000 | 264,151 | |
| Total Assets | 6 | 9 | 14 | 11 | 12 | |
| Accounts payable and accrued expenses | 672,000 | 1 | 892,000 | 972,000 | 583,000 | |
| Accrued compensation | 655,000 | 655,000 | 696,000 | 647,000 | 388,896 | |
| Advances from customers | 55,000 | 85,000 | 60,000 | 51,000 | — | |
| Lease liabilities, current portion | 358,000 | 326,000 | 297,000 | 341,000 | 327,944 | |
| Total current liabilities | 2 | 2 | 2 | 2 | 1 | |
| Lease liabilities, net of current portion | 100,000 | 459,000 | 785,000 | 1 | 1 | |
| Total Liabilities | 2 | 3 | 3 | 3 | 3 | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Preferred stock, value | — | — | — | — | — | |
| Common stock, $0.08 par value, 3,125,000 shares authorized, 2,546,216 and 2,103,154 issued and outstanding at May 31, 2025 and May 31, 2024, respectively | 203,000 | 168,000 | 1 | 1 | 984,571 | |
| Additional paid-in capital | 57 | 55 | 53 | 42 | 39 | |
| Accumulated other comprehensive loss | −105,000 | −102,000 | −110,000 | −74,000 | −47,956 | |
| Accumulated deficit | −53 | −48 | −42 | −35 | −31 | |
| Total Shareholders Equity | 4 | 7 | 12 | 8 | 9 | |
| Total Liabilities and Shareholders Equity | 6 | 9 | 14 | 11 | 12 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-05-31 | FY 2024 2024-05-31 | FY 2023 2023-05-31 | FY 2022 2022-05-31 | FY 2021 2021-05-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 87,000 | 81,000 | 84,000 | 339,096 | 138,267 | |
| Provision (recovery) for allowance for credit losses | 8,000 | −10,000 | 342,000 | −684,000 | 766,434 | |
| Provision (recovery) for inventory reserves | 4,000 | −205,000 | −174,000 | −772,000 | 2 | |
| Share-based compensation | 460,000 | 837,000 | 1 | 1 | — | |
| Amortization of right-of-use asset | 313,000 | 293,000 | 267,000 | 256,000 | 237,588 | |
| Accounts receivable | 209,000 | −215,000 | −291,000 | 1 | −455,614 | |
| Inventories | 882,000 | −115,000 | 534,000 | 2 | −2 | |
| Prepaid expenses and other | −17,000 | 62,000 | 20,000 | 50,000 | 1 | |
| Other assets | 8,000 | −44,000 | 18,000 | 169,000 | −95,958 | |
| Accounts payable and accrued expenses | −466,000 | 246,000 | −80,000 | 389,000 | −403,331 | |
| Accrued compensation | 1,000 | −41,000 | 49,000 | 258,000 | 110,269 | |
| Advances from customers | −30,000 | 25,000 | 9,000 | 51,000 | — | |
| Reduction in lease liabilities | −327,000 | −297,000 | −297,000 | — | — | |
| Net cash used in operating activities | −4 | −5 | −5 | −479,000 | −5 | |
| Purchases of property and equipment | — | −51,000 | −64,000 | −57,000 | −135,856 | |
| Expenditures related to intangibles | −37,000 | −64,000 | −14,000 | −113,000 | −159,727 | |
| Net cash used in investing activities | −37,000 | −115,000 | −78,000 | −170,000 | −295,583 | |
| Gross proceeds from sale of common stock | 2 | — | 10 | 2 | 1 | |
| Deferred offering costs | −3,000 | −81,000 | — | — | — | |
| Costs from sale of common stock | −44,000 | — | −705,000 | −85,000 | −165,919 | |
| Proceeds from exercise of stock options | 15,000 | — | 81,000 | 77,000 | 102,255 | |
| Net cash provided by (used in) financing activities | 2 | −81,000 | 9 | 2 | 1 | |
| Effect of exchange rate changes in cash | −3,000 | 8,000 | −36,000 | −26,000 | −8,115 | |
| Net decrease in cash and cash equivalents | −2 | −6 | 4 | 2 | −4 | |
| Income taxes | 10,000 | 41,000 | 51,000 | 24,000 | — | |
| Deferred Offering Costs | 84,000 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is BIOMERICA INC's CIK number?
BIOMERICA INC's SEC CIK number is 0000073290 (73290). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find BIOMERICA INC's SEC filings?
All of BIOMERICA INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did BIOMERICA INC last report earnings?
BIOMERICA INC (BMRA) most recently filed an earnings 8-K with the SEC on Dec 16, 2021, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001513162-21-000162). This is BIOMERICA INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is BIOMERICA INC's most recent earnings 8-K?
BIOMERICA INC's latest earnings 8-K (Item 2.02) was filed Dec 16, 2021 under accession 0001513162-21-000162. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View BIOMERICA INC's latest earnings 8-K →
Look up any company's CIK number →